Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Strengthens Commercial Momentum Heading Into Mid‑2026
![]() |
Rigel shows accelerating commercial execution and a cash-rich balance sheet that support an under‑valued standing while technical momentum suggests a continued near‑term directional move. Expect fundamentals and clinical catalysts to drive the next phase of re‑rating. |








